E2511: Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Cancer - Lung
Principal Investigator: Igor I Rybkin, MD
The purpose of this research study is to compare the effects, good and/or bad, of veliparib or a dummy pill (placebo) when combined with the standard commonly-used drugs (cisplatin and etoposide) on you and your type of lung cancer to find out which is better.
Patients must have histologically or cytologically confirmed: Extensive stage small cell lung cancer (SCLC) -or- Stage IV large cell neuroendocrine non-small cell lung cancer (NSCLC) -or- Small cell carcinoma of unknown primary or extrapulmonary origin and must be a candidate for systemic therapy. Please call for further eligibility criteria.